These authors contributed equally to this study.
Implications of intratumour heterogeneity for treatment stratification
Article first published online: 10 DEC 2013
Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
The Journal of Pathology
Volume 232, Issue 2, pages 264–273, January 2014
How to Cite
Crockford, A., Jamal-Hanjani, M., Hicks, J. and Swanton, C. (2014), Implications of intratumour heterogeneity for treatment stratification. J. Pathol., 232: 264–273. doi: 10.1002/path.4270
No conflicts of interest were declared.
- Issue published online: 10 DEC 2013
- Article first published online: 10 DEC 2013
- Accepted manuscript online: 20 SEP 2013 12:52PM EST
- Manuscript Accepted: 18 SEP 2013
- Manuscript Revised: 17 SEP 2013
- Manuscript Received: 3 SEP 2013
- intratumour heterogeneity;
- patient-derived xenograft models;
- personalized medicine
Despite advances in the diagnosis and treatment of cancer, the majority of advanced metastatic solid tumours remain incurable. Differential gene expression, somatic mutational status, tumour-specific genetic signatures and micro-environmental selection pressures within individual tumours have implications for the success of predictive assays to guide therapeutic intervention. In this review we discuss the evidence for genetic and phenotypic heterogeneity and its potential implications for clinical decision making. We highlight areas of research that could be improved in order to better stratify patient treatment. We also discuss the predictive potential of patient-derived models of tumour response, including xenograft and cell line-based systems within the context of intratumour heterogeneity. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.